Open Access Full Text Article

ORIGINAL RESEARCH

Association Between Blood Glucose Within 24 Hours After Intensive Care Unit Admission and Prognosis: A Retrospective Cohort Study

This article was published in the following Dove Press journal: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

Lingling Li^{1,2,*} Qinchang Chen^{1,*} Qingui Chen³ Ridong Wu¹ Shenming Wang¹ Chen Yao¹

¹Department of Vascular Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China; ²Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, People's Republic of China; ³Department of Medical Intensive Care Unit, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China

*These authors contributed equally to this work

Department of Vascular Surgery, The First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan Road 2, Guangzhou, People's Republic of China Email shenmingwang@hotmail.com; yaochen@mail.sysu.edu.cn



Purpose: The aim of this study was to evaluate the association between blood glucose within 24 hours after intensive care unit (ICU) admission and prognosis.

Patients and Methods: A retrospective cohort study was conducted using data from a large critical care database. Patients who had a length of ICU stay \geq 24 hours and at least two blood glucose records within 24 hours after ICU admission were included and hospital mortality was chosen as the primary outcome. The average, minimum, and maximum blood glucose within 24 hours after ICU admission were a priori selected as exposures and associations between each exposure and outcomes were assessed after adjusted for potential confounders.

Results: A total of 14,237 patients were included finally with an average age of 62.9±17.7 years and a mean SAPS II on admission of 34 (26–44). Among the study population, 20.2% (2872/14,237) had uncomplicated diabetes, and 6.7% (953/14,237) had complicated diabetes. Lowest hospital mortality rate was observed in the stratum with an average blood glucose ranged 110–140 mg/dL, a minimum blood glucose ranged 80–110 mg/dL, and a maximum blood glucose ranged 110–140 mg/dL. After adjusted for confounders including age, sex, disease severity scores and comorbidities, an average blood glucose ranged 110–140 mg/dL, a minimum blood glucose ranged 80–110 mg/dL, and a maximum blood glucose ranged 80–110 mg/dL, and a maximum blood glucose ranged 80–110 mg/dL, and a maximum blood glucose ranged 110–140 mg/dL were associated with the lowest risk of hospital mortality. Consistent results were found among patients without diabetes in the subgroup analyses stratified by diabetes. **Conclusion:** A range of 110–140 mg/dL for average and maximum blood glucose and a range of 80–110 mg/dL for minimum blood glucose within 24 hours after ICU admission predicted better prognosis especially among patients without diabetes. **Keywords:** blood glucose, critical care, mortality, retrospective studies

Introduction

Hyperglycemia is rather common among patients in intensive care unit (ICU), the prevalence of which ranged from about 40% to nearly 100% based on some previous reports, ^{1–4} although the exact number is not known and may vary according to different study populations and different definitions of hyperglycemia. The mechanisms of hyperglycemia developed in critically ill patients are also not well understood, which are supposed to be complex and may be related to pre-existing diabetes (either previously diagnosed or not) and stress hyperglycemia due to increased counterregulatory hormones.^{5,6} Hyperglycemia was once considered an adaptive response essential for survival and therefore not routinely controlled,⁷ but numerous

Correspondence: Shenming Wang; Chen Yao

observational studies have provided evidences which supported a link between hyperglycemia and poor prognosis of critically ill patients.^{2,8–15} Now it is well accepted that glycemic control plays an important role in the management of patients in ICU,¹⁶ but it is still controversial what the optimal blood glucose range is.^{17,18} Evidences from several clinical trials which investigated various ranges of blood glucose in various populations of ICU patients supported different target blood glucose, and are sometimes contrary.^{19–21} Considering that clinical trials usually only




Figure I Flow chart of the study population.

Notes: Records with potential typographical errors were excluded, including a length of ICU or hospitalization stay less than 0, and the ICU admission or discharge time earlier than the time of death.

Abbreviation: ICU, intensive care unit.

include study populations under specific and strict criteria, of which the characteristics may be quite different to the general population, and that the clinical practice and patient characteristics in ICU are usually highly heterogeneous, evidences from real-world clinical data might provide some clues for trials which aim at determining or validating the ideal target of glycemic control,^{22–24} although it is obvious that what the ideal target of glycemic control could only be answered by clinical trials. Given current available observational studies had either limited sample sizes¹⁰ or specific indications,^{12,14} the study used data from a large critical care database and focused on mixed ICU patients, aiming to evaluate the association between blood glucose within 24 hours after ICU admission and prognosis.

Methods

Study Population

The study used data from the Medical Information Mart for Intensive Care III (MIMIC-III) database, which encompassed a large de-identified population of ICU patients admitted to the Beth Israel Deaconess Medical Center between 2001 and 2012.²⁵ The access to the database was approved by the institutional review boards of both Beth Israel Deaconess Medical Center and Massachusetts Institute of Technology Affiliates after completing the required training course. Informed consent was waived since only anonymous data were used. Patients in the database were included if they met the following inclusion criteria: 1) at least one ICU admission during the hospitalization; 2) at least 2 blood glucose records within 24 hours after ICU admission; 3) only the first hospital admission if there were more than 1 hospital admission in the database; 4) aged ≥ 18 years; 5) length of first ICU stay ≥ 24 hours. Records with potential typographical errors were excluded, including a length of ICU or hospitalization stay less than 0, and the ICU admission or discharge time earlier than the time of death (Figure 1).

Variables Extraction

Structured query language and codes from the MIMIC Code Repository (<u>https://github.com/MIT-LCP/mimic-code</u>)²⁶ were used to extract data from the database, including age, sex, ethnicity, type of admission, Simplified Acute Physiology Score II (SAPS II)²⁷ on admission, mechanical ventilation on first day, renal replacement therapy on first day, Elixhauser Comorbidity Index (SID30),²⁸ and specific comorbidities. For patients who were older than 89 years, the database shifted the date of

Table I Baseline Characteristics of the Study Population

Age (years) 62.9 (17.7) Male 7925 (55.7%) Ethnicity 10.056 (70.6%) Black 1222 (8.6%) Hispanic 472 (3.3%) Asian 351 (2.5%) Native 9 (0.1%) Other 432 (3.0%) Unknown 1695 (11-9%) Type of admission 1695 (11-9%) Elective 1771 (12.4%) Emergency 12.008 (84.3%) Urgent 458 (3.2%) SAPS II on admission 34 (26-44) Mechanical ventilation on first day 6600 (46.4%) Renal replacement therapy on first day 500 (3.5%) Elixhauser Comorbidity Index (SID30) 10 (-19) Comorbidities - - - Congestive heart failure 3852 (27.1%) - Cardia arrhythmias 3940 (27.7%) - Pulmonary circulation disorde	Variables	n (14,237)			
Male 7925 (55.7%) Ethnicity I V White 10.056 (70.6%) Black 1222 (8.6%) Hispanic 472 (3.3%) Asian 351 (2.5%) Native 9 (0.1%) Other 432 (30%) Unknown 1695 (11.9%) Type of admission 1 (2.4%) Elective 1771 (12.4%) Emergency 12.008 (84.3%) Urgent 458 (3.2%) SAPS II on admission 34 (26-44) Mechanical ventilation on first day 6600 (46.4%) Renal replacement therapy on first day 500 (3.5%) Elixhauser Comorbidity Index (SID30) 10 (-19) Comorbidities 70% 70%) Peripheral vascular disorder 998 (70%) Peripheral vascular disorder 998 (12.2%) Hypertension 7416 (52.1%)					
Ethnicity K Y White 10.056 (70.6%) Black 1222 (8.6%) Hispanic 472 (3.3%) Asian 351 (2.5%) Native 9 (0.1%) Other 432 (3.0%) Unknown 1695 (11.9%) Type of admission 1 (12.4%) Elective 1771 (12.4%) Emergency 12,008 (84.3%) Urgent 458 (3.2%) SAPS II on admission 34 (26-44) Mechanical ventilation on first day 6600 (46.4%) Renal replacement therapy on first day 500 (3.5%) Elixhauser Comorbidity Index (SID30) 10 (0-19) Comorbidities 70.2% (12.1%) Pulmonary circulation disorder 998 (70%) Paralysis 512 (3.6%) Other neurological disease 1736 (12.2%) Chronic pulmonary disease 2508 (17.6%)	2 0 <i>j</i>		· ,		
VVnire 10,056 (70.6%) Black 1222 (8.6%) Hispanic 472 (3.3%) Asian 351 (2.5%) Native 9 (0.1%) Other 432 (3.0%) Uhknown 1695 (11.9%) Type of admission 1 (12.008) Elective 1771 (12.4%) Emergency 12.008 (64.3%) Urgent 458 (3.2%) SAPS II on admission 34 (26-44) Mechanical ventilation on first day 6600 (46.4%) Renal replacement therapy on first day 500 (3.5%) Elixhauser Comorbidity Index (SID30) 10 (0-19) Congestive heart failure 3852 (27.1%) Cardiac arrhythmias 3940 (27.7%) Valvular disease 1728 (12.1%) Pulmonary circulation disorder 998 (7.0%) Perpheral vascular disorder 1457 (10.2%) Hypertension 7416 </td <td>Male</td> <td>7925</td> <td>(55.7%)</td>	Male	7925	(55.7%)		
Black 1222 (8.6%) Hispanic 472 (3.3%) Asian 351 (2.5%) Native 9 (0.1%) Other 432 (3.0%) Unknown 1695 (11.9%) Type of admission - - Elective 17711 (12.4%) Emergency 12,008 (84.3%) Urgent 458 (3.2%) SAPS II on admission 34 (26-44) Mechanical ventilation on first day 6600 (46.4%) Renal replacement therapy on first day 500 (3.5%) Elixhauser Comorbidities - - Cardiac arrhythmias 3940 (27.7%) Valvular disease 1728 (12.1%) Pulmonary circulation disorder 998 (7.0%) Peripheral vascular disorder 1457 (10.2%) Hypertension 7416 (52.1%) Other neurological disease 1736 (12.2%) Chronic pulmonary disease 2508	Ethnicity				
Black 1222 (8.6%) Hispanic 472 (3.3%) Asian 351 (2.5%) Native 9 (0.1%) Other 432 (3.0%) Unknown 1695 (11.9%) Type of admission 1 (12.4%) Elective 17711 (12.4%) Emergency 12,008 (84.3%) Urgent 458 (3.2%) SAPS II on admission 34 (26-44) Mechanical ventilation on first day 6600 (46.4%) Renal replacement therapy on first day 500 (3.5%) Eixhauser Comorbidities 7 (27.7%) Cardiac arrhythmias 3940 (27.7%) Valvular disease 1728 (12.1%) Pulmonary circulation disorder 998 (7.0%) Peripheral vascular disorder 1457 (10.2%) Hypertension 7416 (52.1%) Paralysis 512 (3.6%) Other neurological disease 1736	,	10,056	(70.6%)		
Hispanic 472 (3.3%) Asian 351 (2.5%) Native 9 (0.1%) Other 432 (3.0%) Unknown 1695 (11.9%) Type of admission - - Elective 1771 (12.4%) Emergency 12.008 (84.3%) Urgent 458 (3.2%) SAPS II on admission 34 (26-44) Mechanical ventilation on first day 6600 (46.4%) Renal replacement therapy on first day 500 (3.5%) Elixhauser Comorbidity Index (SID30) 10 (0-19) Congestive heart failure 3852 (27.1%) Cardiac arrhythmias 3940 (27.7%) Valvular disease 1728 (12.2%) Pulmonary circulation disorder 988 (7.0%) Paralysis 512 (3.6%) Other neurological disease 1736 (12.2%) Chonic pulmonary disease 2508 (17.6%) Uncomplicated diabetes <td>Black</td> <td>ŕ</td> <td>` '</td>	Black	ŕ	` '		
Asian 351 (2.5%) Native 9 (0.1%) Other 432 (3.0%) Unknown 1695 (11.9%) Type of admission 1 (12.4%) Elective 1771 (12.4%) Emergency 12.008 (84.3%) Urgent 458 (3.2%) SAPS II on admission 34 (26-44) Mechanical ventilation on first day 6600 (46.4%) Renal replacement therapy on first day 500 (3.5%) Elixhauser Comorbidity Index (SID30) 10 (0-19) Comorbidities	Hispanic	472	· ,		
Native 9 (0.1%) Other 432 (3.0%) Unknown 1695 (11.9%) Type of admission 1 (12.4%) Emergency 12.008 (84.3%) Urgent 458 (3.2%) SAPS II on admission 34 (26-44) Mechanical ventilation on first day 6600 (46.4%) Renal replacement therapy on first day 500 (3.5%) Elixhauser Comorbidity Index (SID30) 10 (0-19) Congestive heart failure 3852 (27.1%) Cardiac arrhythmias 3940 (27.7%) Valvular disease 1728 (12.1%) Pulmonary circulation disorder 998 (7.0%) Peripheral vascular disorder 1457 (10.2%) Hypertension 7416 (52.1%) Other neurological disease 2508 (17.6%) Uncomplicated diabetes 2503 (6.7%) Hypothyroidism 1335 (9.4%) Renal failure 1970 (13.8%)	I	351	` ´		
Other 432 (3.0%) Unknown 1695 (11.9%) Type of admission I I Elective 1771 (12.4%) Emergency 12,008 (84.3%) Urgent 458 (3.2%) SAPS II on admission 34 (26-44) Mechanical ventilation on first day 6600 (46.4%) Renal replacement therapy on first day 500 (3.5%) Elixhauser Comorbidity Index (SID30) 10 (0-19) Comorbidities - - Congestive heart failure 3852 (27.1%) Cardiac arrhythmias 3940 (27.7%) Valvular disease 1728 (12.1%) Pulmonary circulation disorder 998 (7.0%) Peripheral vascular disorder 1457 (10.2%) Hypertension 7416 (52.1%) Paralysis 512 (3.6%) Other neurological disease 1736 (12.2%) Chronic pulmonary disease 2872 (20.2%)	Native	9	(0.1%)		
Unknown 1695 (11.9%) Type of admission ////////////////////////////////////	Other	432	· ,		
Elective 1771 (12.4%) Emergency 12,008 (84.3%) Urgent 458 (3.2%) SAPS II on admission 34 (26-44) Mechanical ventilation on first day 6600 (46.4%) Renal replacement therapy on first day 500 (3.5%) Elixhauser Comorbidity Index (SID30) 10 (0-19) Comorbidities - - Congestive heart failure 3852 (27.1%) Cardiac arrhythmias 3940 (27.7%) Valvular disease 1728 (12.1%) Puripheral vascular disorder 998 (7.0%) Peripheral vascular disorder 1457 (10.2%) Hypertension 7416 (52.1%) Other neurological disease 1736 (12.2%) Complicated diabetes 2872 (20.2%) Complicated diabetes 953 (6.7%) Hypothyroidism 1335 (9.4%) Renal failure 1970 (13.8%) Liver disease 1245 (8.7%) <td>Unknown</td> <td>1695</td> <td>· ,</td>	Unknown	1695	· ,		
Emergency Urgent 12,008 (84.3%) SAPS II on admission 34 (26-44) Mechanical ventilation on first day 6600 (46.4%) Renal replacement therapy on first day 500 (3.5%) Elixhauser Comorbidity Index (SID30) 10 (0-19) Comorbidities	Type of admission				
Urgent 458 (3.2%) SAPS II on admission 34 (26-44) Mechanical ventilation on first day 6600 (46.4%) Renal replacement therapy on first day 500 (3.5%) Elixhauser Comorbidity Index (SID30) 10 (0-19) Comorbidities 200 (27.7%) Cardiac arrhythmias 3940 (27.7%) Valvular disease 1728 (12.1%) Pulmonary circulation disorder 998 (7.0%) Peripheral vascular disorder 1457 (10.2%) Hypertension 7416 (52.1%) Paralysis 512 (3.6%) Other neurological disease 1736 (12.2%) Chronic pulmonary disease 2508 (17.6%) Uncomplicated diabetes 953 (6.7%) Hypothyroidism 1335 (9.4%) Renal failure 1970 (13.8%) Liver disease 1245 (8.7%) Peptic ulcer 17 (0.1%) AIDS 165 (1.2%) </td <td></td> <td>1771</td> <td>(12.4%)</td>		1771	(12.4%)		
Urgent 458 (3.2%) SAPS II on admission 34 (26-44) Mechanical ventilation on first day 6600 (46.4%) Renal replacement therapy on first day 500 (3.5%) Elixhauser Comorbidity Index (SID30) 10 (0-19) Comorbidities 200 (27.7%) Cardiac arrhythmias 3940 (27.7%) Valvular disease 1728 (12.1%) Pulmonary circulation disorder 998 (7.0%) Peripheral vascular disorder 1457 (10.2%) Hypertension 7416 (52.1%) Paralysis 512 (3.6%) Other neurological disease 1736 (12.2%) Chronic pulmonary disease 2508 (17.6%) Uncomplicated diabetes 953 (6.7%) Hypothyroidism 1335 (9.4%) Renal failure 1970 (13.8%) Liver disease 1245 (8.7%) Peptic ulcer 17 (0.1%) AIDS 165 (1.2%) </td <td>Emergency</td> <td>12,008</td> <td>(84.3%)</td>	Emergency	12,008	(84.3%)		
SAPS II on admission 34 (26-44) Mechanical ventilation on first day 6600 (46.4%) Renal replacement therapy on first day 500 (3.5%) Elixhauser Comorbidity Index (SID30) 10 (0-19) Compestive heart failure 3852 (27.1%) Cardiac arrhythmias 3940 (27.7%) Valvular disease 1728 (12.1%) Pulmonary circulation disorder 998 (7.0%) Peripheral vascular disorder 1457 (10.2%) Hypertension 7416 (52.1%) Paralysis 512 (3.6%) Other neurological disease 1736 (12.2%) Chronic pulmonary disease 2508 (17.6%) Uncomplicated diabetes 2872 (20.2%) Complicated diabetes 953 (6.7%) Hypothyroidism 1335 (9.4%) Renal failure 1970 (13.8%) Liver disease 1245 (8.7%) Peptic ulcer 17 (0.1%) AIDS 165	• ,	ŕ	` '		
Mechanical ventilation on first day 6600 (46.4%) Renal replacement therapy on first day 500 (3.5%) Elixhauser Comorbidity Index (SID30) 10 (0-19) Comorbidities 3852 (27.1%) Cardiac arrhythmias 3940 (27.7%) Valvular disease 1728 (12.1%) Pulmonary circulation disorder 998 (7.0%) Peripheral vascular disorder 1457 (10.2%) Hypertension 7416 (52.1%) Paralysis 512 (3.6%) Other neurological disease 1736 (12.2%) Complicated diabetes 2872 (20.2%) Complicated diabetes 2872 (20.2%) Complicated diabetes 953 (6.7%) Hypothyroidism 1335 (9.4%) Renal failure 1970 (13.8%) Liver disease 1245 (8.7%) Peptic ulcer 17 (0.1%) AIDS 165 (1.2%) Lymphoma 262 (1.8%) <td></td> <td></td> <td>. ,</td>			. ,		
Renal replacement therapy on first day Elixhauser Comorbidity Index (SID30) 500 (3.5%) (0-19) Comorbidities (0-19) Comorbidities 3852 (27.1%) Cardiac arrhythmias 3940 (27.7%) Valvular disease 1728 (12.1%) Pulmonary circulation disorder 998 (7.0%) Peripheral vascular disorder 1457 (10.2%) Hypertension 7416 (52.1%) Paralysis 512 (3.6%) Other neurological disease 1736 (12.2%) Complicated diabetes 2872 (20.2%) Complicated diabetes 2872 (20.2%) Complicated diabetes 953 (6.7%) Hypothyroidism 1335 (9.4%) Renal failure 1970 (13.8%) Liver disease 1245 (8.7%) Peptic ulcer 17 (0.1%) AIDS 165 (1.2%) Lymphoma 262 (1.8%) Metastatic cancer 879 (6.2%)			` '		
Elixhauser Comorbidity Index (SID30) 10 (0-19) Comorbidities	Mechanical ventilation on first day		(46.4%)		
Comorbidities Image: Compositive heart failure 3852 (27.1%) Cardiac arrhythmias 3940 (27.7%) Valvular disease 1728 (12.1%) Pulmonary circulation disorder 998 (7.0%) Peripheral vascular disorder 1457 (10.2%) Hypertension 7416 (52.1%) Paralysis 512 (3.6%) Other neurological disease 1736 (12.2%) Chronic pulmonary disease 2508 (17.6%) Uncomplicated diabetes 2872 (20.2%) Complicated diabetes 953 (6.7%) Hypothyroidism 1335 (9.4%) Renal failure 1970 (13.8%) Liver disease 1245 (8.7%) Peptic ulcer 17 (0.1%) AIDS 165 (1.2%) Lymphoma 262 (1.8%) Metastatic cancer 879 (6.2%) Solid tumor 840 (5.9%) Rheumatoid arthritis 413 (2.9%)	Renal replacement therapy on first day	500	(3.5%)		
Congestive heart failure 3852 (27.1%) Cardiac arrhythmias 3940 (27.7%) Valvular disease 1728 (12.1%) Pulmonary circulation disorder 998 (7.0%) Peripheral vascular disorder 1457 (10.2%) Hypertension 7416 (52.1%) Paralysis 512 (3.6%) Other neurological disease 1736 (12.2%) Chronic pulmonary disease 2508 (17.6%) Uncomplicated diabetes 2872 (20.2%) Complicated diabetes 953 (6.7%) Hypothyroidism 1335 (9.4%) Renal failure 1970 (13.8%) Liver disease 1245 (8.7%) Peptic ulcer 17 (0.1%) AIDS 165 (1.2%) Lymphoma 262 (1.8%) Metastatic cancer 879 (6.2%) Solid tumor 840 (5.9%) Rheumatoid arthritis 413 (2.9%) Coagulopathy	Elixhauser Comorbidity Index (SID30)	10	(0–19)		
Cardiac arrhythmias 3940 (27.7%) Valvular disease 1728 (12.1%) Pulmonary circulation disorder 998 (7.0%) Peripheral vascular disorder 1457 (10.2%) Hypertension 7416 (52.1%) Paralysis 512 (3.6%) Other neurological disease 1736 (12.2%) Chronic pulmonary disease 2508 (17.6%) Uncomplicated diabetes 2872 (20.2%) Complicated diabetes 953 (6.7%) Hypothyroidism 1335 (9.4%) Renal failure 1970 (13.8%) Liver disease 1245 (8.7%) Peptic ulcer 17 (0.1%) AIDS 165 (1.2%) Lymphoma 262 (1.8%) Metastatic cancer 879 (6.2%) Solid tumor 840 (5.9%) Rheumatoid arthritis 413 (2.9%) Coagulopathy 1846 (13.0%) Obesity 747	Comorbidities				
Valvular disease I728 (I.2.1%) Pulmonary circulation disorder 998 (7.0%) Peripheral vascular disorder 1457 (10.2%) Hypertension 7416 (52.1%) Paralysis 512 (3.6%) Other neurological disease 1736 (12.2%) Chronic pulmonary disease 2508 (17.6%) Uncomplicated diabetes 2872 (20.2%) Complicated diabetes 953 (6.7%) Hypothyroidism 1335 (9.4%) Renal failure 1970 (13.8%) Liver disease 1245 (8.7%) Peptic ulcer 17 (0.1%) AIDS 165 (1.2%) Lymphoma 262 (1.8%) Metastatic cancer 879 (6.2%) Solid tumor 840 (5.9%) Rheumatoid arthritis 413 (2.9%) Coagulopathy 1846 (13.0%) Obesity 747 (5.2%) Weight loss 671	Congestive heart failure	3852	(27.1%)		
Pulmonary circulation disorder 998 (7.0%) Peripheral vascular disorder 1457 (10.2%) Hypertension 7416 (52.1%) Paralysis 512 (3.6%) Other neurological disease 1736 (12.2%) Chronic pulmonary disease 2508 (17.6%) Uncomplicated diabetes 2872 (20.2%) Complicated diabetes 953 (6.7%) Hypothyroidism 1335 (9.4%) Renal failure 1970 (13.8%) Liver disease 1245 (8.7%) Peptic ulcer 17 (0.1%) AIDS 165 (1.2%) Lymphoma 262 (1.8%) Metastatic cancer 879 (6.2%) Solid tumor 840 (5.9%) Rheumatoid arthritis 413 (2.9%) Coagulopathy 1846 (13.0%) Obesity 747 (5.2%) Weight loss 671 (4.7%) Fluid and electrolyte disorders 4945<	Cardiac arrhythmias	3940	(27.7%)		
Pulmonary circulation disorder 998 (7.0%) Peripheral vascular disorder 1457 (10.2%) Hypertension 7416 (52.1%) Paralysis 512 (3.6%) Other neurological disease 1736 (12.2%) Chronic pulmonary disease 2508 (17.6%) Uncomplicated diabetes 2872 (20.2%) Complicated diabetes 953 (6.7%) Hypothyroidism 1335 (9.4%) Renal failure 1970 (13.8%) Liver disease 1245 (8.7%) Peptic ulcer 17 (0.1%) AIDS 165 (1.2%) Lymphoma 262 (1.8%) Metastatic cancer 879 (6.2%) Solid tumor 840 (5.9%) Rheumatoid arthritis 413 (2.9%) Coagulopathy 1846 (13.0%) Obesity 747 (5.2%) Weight loss 671 (4.7%) Fluid and electrolyte disorders 4945<	Valvular disease	1728	· /		
Peripheral vascular disorder 1457 (10.2%) Hypertension 7416 (52.1%) Paralysis 512 (3.6%) Other neurological disease 1736 (12.2%) Chronic pulmonary disease 2508 (17.6%) Uncomplicated diabetes 2872 (20.2%) Complicated diabetes 953 (6.7%) Hypothyroidism 1335 (9.4%) Renal failure 1970 (13.8%) Liver disease 1245 (8.7%) Peptic ulcer 17 (0.1%) AIDS 165 (1.2%) Lymphoma 262 (1.8%) Metastatic cancer 879 (6.2%) Solid tumor 840 (5.9%) Rheumatoid arthritis 413 (2.9%) Coagulopathy 1846 (13.0%) Obesity 747 (5.2%) Weight loss 671 (4.7%) Fluid and electrolyte disorders 4945 (34.7%) Blood loss anemia 347 (2.4%) Deficiency anemia 2643 (18.6%)	Pulmonary circulation disorder	998	(7.0%)		
Paralysis 512 (3.6%) Other neurological disease 1736 (12.2%) Chronic pulmonary disease 2508 (17.6%) Uncomplicated diabetes 2872 (20.2%) Complicated diabetes 953 (6.7%) Hypothyroidism 1335 (9.4%) Renal failure 1970 (13.8%) Liver disease 1245 (8.7%) Peptic ulcer 17 (0.1%) AIDS 165 (1.2%) Lymphoma 262 (1.8%) Metastatic cancer 879 (6.2%) Solid tumor 840 (5.9%) Rheumatoid arthritis 413 (2.9%) Coagulopathy 1846 (13.0%) Obesity 747 (5.2%) Weight loss 671 (4.7%) Fluid and electrolyte disorders 4945 (34.7%) Blood loss anemia 347 (2.4%) Deficiency anemia 347 (2.4%) Alcohol abuse 1373 (9.6%) </td <td>Peripheral vascular disorder</td> <td>1457</td> <td>(10.2%)</td>	Peripheral vascular disorder	1457	(10.2%)		
Other neurological disease 1736 (12.2%) Chronic pulmonary disease 2508 (17.6%) Uncomplicated diabetes 2872 (20.2%) Complicated diabetes 953 (6.7%) Hypothyroidism 1335 (9.4%) Renal failure 1970 (13.8%) Liver disease 1245 (8.7%) Peptic ulcer 17 (0.1%) AIDS 165 (1.2%) Lymphoma 262 (1.8%) Metastatic cancer 879 (6.2%) Solid tumor 840 (5.9%) Rheumatoid arthritis 413 (2.9%) Coagulopathy 1846 (13.0%) Obesity 747 (5.2%) Weight loss 671 (4.7%) Fluid and electrolyte disorders 4945 (34.7%) Blood loss anemia 347 (2.4%) Deficiency anemia 347 (2.4%) Alcohol abuse 1373 (9.6%) Drug abuse 579 (4.1%)<	Hypertension	7416	(52.1%)		
Chronic pulmonary disease 2508 (17.6%) Uncomplicated diabetes 2872 (20.2%) Complicated diabetes 953 (6.7%) Hypothyroidism 1335 (9.4%) Renal failure 1970 (13.8%) Liver disease 1245 (8.7%) Peptic ulcer 17 (0.1%) AIDS 165 (1.2%) Lymphoma 262 (1.8%) Metastatic cancer 879 (6.2%) Solid tumor 840 (5.9%) Rheumatoid arthritis 413 (2.9%) Coagulopathy 1846 (13.0%) Obesity 747 (5.2%) Weight loss 671 (4.7%) Fluid and electrolyte disorders 4945 (34.7%) Blood loss anemia 347 (2.4%) Deficiency anemia 347 (2.4%) Deficiency anemia 2643 (18.6%) Alcohol abuse 1373 (9.6%) Drug abuse 579 (4.1%)	Paralysis	512	(3.6%)		
Uncomplicated diabetes 2872 (20.2%) Complicated diabetes 953 (6.7%) Hypothyroidism 1335 (9.4%) Renal failure 1970 (13.8%) Liver disease 1245 (8.7%) Peptic ulcer 17 (0.1%) AIDS 165 (1.2%) Lymphoma 262 (1.8%) Metastatic cancer 879 (6.2%) Solid tumor 840 (5.9%) Rheumatoid arthritis 413 (2.9%) Coagulopathy 1846 (13.0%) Obesity 747 (5.2%) Weight loss 671 (4.7%) Fluid and electrolyte disorders 4945 (34.7%) Blood loss anemia 347 (2.4%) Deficiency anemia 347 (2.4%) Alcohol abuse 1373 (9.6%) Drug abuse 579 (4.1%) Psychoses 640 (4.5%)	Other neurological disease	1736	(12.2%)		
Complicated diabetes 953 (6.7%) Hypothyroidism 1335 (9.4%) Renal failure 1970 (13.8%) Liver disease 1245 (8.7%) Peptic ulcer 17 (0.1%) AIDS 165 (1.2%) Lymphoma 262 (1.8%) Metastatic cancer 879 (6.2%) Solid tumor 840 (5.9%) Rheumatoid arthritis 413 (2.9%) Coagulopathy 1846 (13.0%) Obesity 747 (5.2%) Weight loss 671 (4.7%) Fluid and electrolyte disorders 4945 (34.7%) Blood loss anemia 347 (2.4%) Deficiency anemia 347 (2.4%) Deficiency anemia 2643 (18.6%) Alcohol abuse 1373 (9.6%) Drug abuse 579 (4.1%) Psychoses 640 (4.5%)	Chronic pulmonary disease	2508	(17.6%)		
Hypothyroidism 1335 (9.4%) Renal failure 1970 (13.8%) Liver disease 1245 (8.7%) Peptic ulcer 17 (0.1%) AIDS 165 (1.2%) Lymphoma 262 (1.8%) Metastatic cancer 879 (6.2%) Solid tumor 840 (5.9%) Rheumatoid arthritis 413 (2.9%) Coagulopathy 1846 (13.0%) Obesity 747 (5.2%) Weight loss 671 (4.7%) Blood loss anemia 347 (2.4%) Deficiency anemia 2643 (18.6%) Alcohol abuse 1373 (9.6%) Drug abuse 579 (4.1%) Psychoses 640 (4.5%)	Uncomplicated diabetes	2872	(20.2%)		
Renal failure 1970 (13.8%) Liver disease 1245 (8.7%) Peptic ulcer 17 (0.1%) AIDS 165 (1.2%) Lymphoma 262 (1.8%) Metastatic cancer 879 (6.2%) Solid tumor 840 (5.9%) Rheumatoid arthritis 413 (2.9%) Coagulopathy 1846 (13.0%) Obesity 747 (5.2%) Weight loss 671 (4.7%) Fluid and electrolyte disorders 4945 (34.7%) Blood loss anemia 347 (2.4%) Deficiency anemia 2643 (18.6%) Alcohol abuse 1373 (9.6%) Drug abuse 579 (4.1%) Psychoses 640 (4.5%)	Complicated diabetes	953	(6.7%)		
Liver disease 1245 (8.7%) Peptic ulcer 17 (0.1%) AIDS 165 (1.2%) Lymphoma 262 (1.8%) Metastatic cancer 879 (6.2%) Solid tumor 840 (5.9%) Rheumatoid arthritis 413 (2.9%) Coagulopathy 1846 (13.0%) Obesity 747 (5.2%) Weight loss 671 (4.7%) Fluid and electrolyte disorders 4945 (34.7%) Blood loss anemia 347 (2.4%) Deficiency anemia 2643 (18.6%) Alcohol abuse 1373 (9.6%) Drug abuse 579 (4.1%) Psychoses 640 (4.5%)	Hypothyroidism	1335	(9.4%)		
Peptic ulcer 17 (0.1%) AIDS 165 (1.2%) Lymphoma 262 (1.8%) Metastatic cancer 879 (6.2%) Solid tumor 840 (5.9%) Rheumatoid arthritis 413 (2.9%) Coagulopathy 1846 (13.0%) Obesity 747 (5.2%) Weight loss 671 (4.7%) Fluid and electrolyte disorders 4945 (34.7%) Blood loss anemia 347 (2.4%) Deficiency anemia 2643 (18.6%) Alcohol abuse 1373 (9.6%) Drug abuse 579 (4.1%) Psychoses 640 (4.5%)	Renal failure	1970	(13.8%)		
AIDS 165 (1.2%) Lymphoma 262 (1.8%) Metastatic cancer 879 (6.2%) Solid tumor 840 (5.9%) Rheumatoid arthritis 413 (2.9%) Coagulopathy 1846 (13.0%) Obesity 747 (5.2%) Weight loss 671 (4.7%) Fluid and electrolyte disorders 4945 (34.7%) Blood loss anemia 347 (2.4%) Deficiency anemia 2643 (18.6%) Alcohol abuse 1373 (9.6%) Drug abuse 579 (4.1%) Psychoses 640 (4.5%)	Liver disease	1245	(8.7%)		
Lymphoma 262 (1.8%) Metastatic cancer 879 (6.2%) Solid tumor 840 (5.9%) Rheumatoid arthritis 413 (2.9%) Coagulopathy 1846 (13.0%) Obesity 747 (5.2%) Weight loss 671 (4.7%) Fluid and electrolyte disorders 4945 (34.7%) Blood loss anemia 347 (2.4%) Deficiency anemia 2643 (18.6%) Alcohol abuse 1373 (9.6%) Drug abuse 579 (4.1%) Psychoses 640 (4.5%)	Peptic ulcer	17	(0.1%)		
Metastatic cancer 879 (6.2%) Solid tumor 840 (5.9%) Rheumatoid arthritis 413 (2.9%) Coagulopathy 1846 (13.0%) Obesity 747 (5.2%) Weight loss 671 (4.7%) Fluid and electrolyte disorders 4945 (34.7%) Blood loss anemia 347 (2.4%) Deficiency anemia 2643 (18.6%) Alcohol abuse 1373 (9.6%) Drug abuse 579 (4.1%) Psychoses 640 (4.5%)	AIDS	165	(1.2%)		
Solid tumor 840 (5.9%) Rheumatoid arthritis 413 (2.9%) Coagulopathy 1846 (13.0%) Obesity 747 (5.2%) Weight loss 671 (4.7%) Fluid and electrolyte disorders 4945 (34.7%) Blood loss anemia 347 (2.4%) Deficiency anemia 2643 (18.6%) Alcohol abuse 1373 (9.6%) Drug abuse 579 (4.1%) Psychoses 640 (4.5%)	Lymphoma	262	(1.8%)		
Rheumatoid arthritis 413 (2.9%) Coagulopathy 1846 (13.0%) Obesity 747 (5.2%) Weight loss 671 (4.7%) Fluid and electrolyte disorders 4945 (34.7%) Blood loss anemia 347 (2.4%) Deficiency anemia 2643 (18.6%) Alcohol abuse 1373 (9.6%) Drug abuse 579 (4.1%) Psychoses 640 (4.5%)	Metastatic cancer	879	(6.2%)		
Coagulopathy 1846 (13.0%) Obesity 747 (5.2%) Weight loss 671 (4.7%) Fluid and electrolyte disorders 4945 (34.7%) Blood loss anemia 347 (2.4%) Deficiency anemia 2643 (18.6%) Alcohol abuse 1373 (9.6%) Drug abuse 579 (4.1%) Psychoses 640 (4.5%)	Solid tumor	840	(5.9%)		
Obesity 747 (5.2%) Weight loss 671 (4.7%) Fluid and electrolyte disorders 4945 (34.7%) Blood loss anemia 347 (2.4%) Deficiency anemia 2643 (18.6%) Alcohol abuse 1373 (9.6%) Drug abuse 579 (4.1%) Psychoses 640 (4.5%)	Rheumatoid arthritis	413	(2.9%)		
Weight loss 671 (4.7%) Fluid and electrolyte disorders 4945 (34.7%) Blood loss anemia 347 (2.4%) Deficiency anemia 2643 (18.6%) Alcohol abuse 1373 (9.6%) Drug abuse 579 (4.1%) Psychoses 640 (4.5%)	Coagulopathy	1846	(13.0%)		
Fluid and electrolyte disorders 4945 (34.7%) Blood loss anemia 347 (2.4%) Deficiency anemia 2643 (18.6%) Alcohol abuse 1373 (9.6%) Drug abuse 579 (4.1%) Psychoses 640 (4.5%)	Obesity	747	(5.2%)		
Blood loss anemia 347 (2.4%) Deficiency anemia 2643 (18.6%) Alcohol abuse 1373 (9.6%) Drug abuse 579 (4.1%) Psychoses 640 (4.5%)	Weight loss	671	(4.7%)		
Deficiency anemia 2643 (18.6%) Alcohol abuse 1373 (9.6%) Drug abuse 579 (4.1%) Psychoses 640 (4.5%)	Fluid and electrolyte disorders	4945	(34.7%)		
Alcohol abuse 1373 (9.6%) Drug abuse 579 (4.1%) Psychoses 640 (4.5%)	Blood loss anemia	347	(2.4%)		
Drug abuse 579 (4.1%) Psychoses 640 (4.5%)	Deficiency anemia	2643	(18.6%)		
Psychoses 640 (4.5%)	Alcohol abuse	1373	(9.6%)		
· · · · · · · · · · · · · · · · · · ·	Drug abuse	579	(4.1%)		
Depression 168 (8.2%)	Psychoses	640	(4.5%)		
	Depression	1168	(8.2%)		

Notes: Data are expressed as mean (standard deviation), median (25th–75th percentiles) or counts (percentages).

 $\label{eq:abbreviations: SAPS II, simplified acute physiology score II; AIDS, acquired immune deficiency syndrome.$

Glucose (mg/dL)	n	⊼±SD (mg/dL)	Hospital Mortality	ICU Mortality	28-Day Mortality
Average of records					
<60	20	52.6±6.5	I (5.0%)	0 (0.0%)	0 (0.0%)
60–80	278	72.7±5.2	26 (9.4%)	4 (1.4%)	35 (12.6%)
80-110	3019	98.2±7.8	159 (5.3%)	13 (0.4%)	224 (7.4%)
110-140	5162	124.4±8.6	238 (4.6%)	23 (0.4%)	337 (6.5%)
140-180	3512	156.3±11.1	212 (6.0%)	30 (0.9%)	276 (7.9%)
180-200	801	189.3±5.7	61 (7.6%)	12 (1.5%)	77 (9.6%)
≥200	1445	254.9±64.9	103 (7.1%)	30 (2.1%)	127 (8.8%)
Minimum record					
<60	280	48.1±9.6	25 (8.9%)	4 (1.4%)	3 (. %)
60–80	1009	71.8±5.5	81 (8.0%)	8 (0.8%)	103 (10.2%)
80-110	5364	96.2±8.2	240 (4.5%)	23 (0.4%)	347 (6.5%)
110-140	4757	122.7±8.4	244 (5.1%)	27 (0.6%)	331 (7.0%)
140-180	2032	154.6±10.8	153 (7.5%)	33 (1.6%)	193 (9.5%)
180-200	334	188.2±5.9	23 (6.9%)	5 (1.5%)	27 (8.1%)
≥200	461	240.1±41.4	34 (7.4%)	12 (2.6%)	44 (9.5%)
Maximum record					
<60	8	53.6±8.0	I (12.5%)	0 (0.0%)	0 (0.0%)
<60 60–80	• 113	53.6±8.0 73.4±4.8	1 (12.5%)	0 (0.0%) 2 (1.8%)	0 (0.0%) 15 (13.3%)
80-80 80-110	1884	73.4±4.8 98.6±7.7	96 (5.1%)	2 (1.8%) 6 (0.3%)	13 (13.3%)
110-140	4046	125.0±8.4	177 (4.4%)	8 (0.3%) 20 (0.5%)	261 (6.5%)
110-140	4048	123.0±0.4	235 (5.8%)	26 (0.5%)	303 (7.5%)
140-180	1102	137.1±11.3	65 (5.9%)	28 (0.8%) 7 (0.6%)	83 (7.5%)
180–200 ≥200	3062	291.2±131.9	212 (6.9%)	51 (1.7%)	272 (8.9%)
-200	5002	271.22131.7	212 (0.7%)	51 (1.7%)	272 (3.7%)

Table 2 Clinical Outcomes of the Study Population Stratified by	
Blood Glucose Levels Within 24 Hours After ICU Admission	

Table 3 Lengths of ICU/Hospital Stay of the Study PopulationStratified by Blood Glucose Levels Within 24 Hours After ICUAdmission

Glucose (mg/dL)	n	x±SD (mg/dL)	Length of ICU Stay (Days)	Length of Hospital Stay (Days)
Average of				
records				
<60	20	52.6±6.5	3.2 (1.9-8.3)	11.5 (7.2–16.9)
60–80	278	72.7±5.2	2.7 (1.7-4.9)	8.4 (5.4–16.1)
80-110	3019	98.2±7.8	2.4 (1.6–4.2)	7.8 (4.8–13.7)
110-140	5162	124.4±8.6	2.7 (1.8–4.9)	8.6 (5.4–14.5)
140-180	3512	156.3±11.1	3.0 (1.9–5.9)	9.2 (6.0–15.9)
180-200	801	189.3±5.7	3.0 (1.9–5.9)	9.2 (5.7–15.7)
≥200	1445	254.9±64.9	3.0 (1.9–6.1)	9.2 (5.5–15.7)
Minimum				
record				
<60	280	48.1±9.6	3.1 (1.9-6.9)	10.0 (5.7–18.8)
60–80	1009	71.8±5.5	2.7 (1.8–5.0)	8.7 (5.6–15.8)
80-110	5364	96.2±8.2	2.6 (1.7–4.7)	8.0 (5.0–13.7)
110-140	4757	I 22.7±8.4	2.9 (1.8–5.1)	9.0 (5.8–15.6)
140-180	2032	154.6±10.8	3.0 (1.9–5.8)	9.0 (5.8–15.1)
180-200	334	188.2±5.9	3.0 (1.8–6.5)	9.2 (5.8–17.0)
≥200	461	240.1±41.4	3.1 (1.9–6.6)	9.8 (5.6–15.4)
Maximum				
record				
<60	8	53.6±8.0	2.6 (1.7–4.4)	9.2 (6.3–14.3)
60–80	113	73.4±4.8	2.9 (1.7–5.1)	7.9 (5.5–15.1)
80-110	1884	98.6±7.7	2.3 (1.6-4.0)	7.5 (4.5–13.3)
110-140	4046	125.0±8.4	2.6 (1.7–4.4)	8.2 (5.2–13.7)
140-180	4022	157.1±11.3	3.0 (1.9–5.7)	9.1 (5.9–15.7)
180-200	1102	188.8±5.6	3.0 (1.9–5.7)	9.1 (5.9–15.6)
≥200	3062	291.2±131.9	3.1 (1.9-6.1)	9.2 (5.6–16.1)

Abbreviations: ICU, intensive care unit; SD, standard deviation.

Abbreviations: ICU, intensive care unit; SD, standard deviation.

birth to exactly 300 years before to obscure their ages, and these records were corrected (by minus 300 and plus 89) before analysis.

Exposures

Blood glucose records were extracted according to Logical Observation Identifiers Names and Codes (LOINC) 2345–7. The average, minimum, and maximum blood glucose within 24 hours after ICU admission were a priori selected as exposures. Blood glucose levels were also a priori categorized as $<60, 60-80, 80-110, 110-140, 140-180, 180-200, and \geq 200 mg/dL.$

Outcomes

Hospital mortality, ICU mortality, and 28-day mortality were studied as outcomes, among which hospital mortality was chosen as the primary outcome. For patients with multiple ICU admissions during the hospitalization, ICU mortality and lengths of ICU stay only referred to the first ICU

Statistical Analysis

hospitalization.

Data were expressed as mean \pm standard deviation, median (25th-75th percentiles), or counts (percentages). Associations between each exposure and outcomes were assessed using multivariable logistic regression or Cox regression adjusted for age, sex, ethnicity, type of admission, SAPS II on admission, mechanical ventilation on first day, renal replacement therapy on first day, and Elixhauser Comorbidity Index (SID30). Subgroup analyses stratified by diabetes were also conducted after the adjustment. P values less than 0.05 were considered to indicate statistical significance. IBM SPSS Statistics for Windows, version 25.0 (IBM Corp., Armonk, NY, USA) was used for statistical analyses. The forest plots were plotted out using R package "ggforestplot".

Results Baseline Characteristics of the Study Population

14,237 patients were included finally with an average age of 62.9 ± 17.7 years and a mean SAPS II on admission of 34 (26–44). Among the study population, 55.7% (7925/14,237) were male, 20.2% (2872/14,237) had uncomplicated diabetes, and 6.7% (953/14,237) had complicated diabetes, 46.4% (6600/14,237) needed mechanical ventilation on the first day after ICU admission, and 3.5% (500/

14,237) needed renal replacement therapy on the first day after ICU admission (Table 1).

Clinical Outcomes Stratified by Blood Glucose Levels

For average blood glucose and maximum blood glucose, the stratum ranged 110–140 mg/dL had the lowest hospital mortality rate (4.6% and 4.4%, respectively). However, the lowest hospital mortality rate was observed in the stratum with minimum blood glucose ranged 80–110 mg/dL




Figure 2 Associations between average blood glucose levels within 24 hours after ICU admission and hospital mortality. Notes: Adjusted for age, sex, ethnicity, type of admission, SAPS II on admission, mechanical ventilation on first day, renal replacement therapy on first day, and Elixhauser Comorbidity Index (SID30).

(4.5%), followed by a level ranged 110–140 mg/dL (5.1%). Results of ICU mortality, 28-day mortality, and lengths of ICU or hospital stay were presented in Tables 2 and 3.

Associations Between Blood Glucose Levels and Clinical Outcomes

When the stratum of blood glucose ranged 110–140 mg/dL was taken as the reference and after adjusted for confounders including age, sex, disease severity scores and comorbidities, an average blood glucose ranged 110–140 mg/dL and a maximum blood glucose ranged 110–140 mg/dL

were both associated with the lowest risk of hospital mortality (Figures 2 and 3). However, a minimum blood glucose ranged 80–110 mg/dL was associated with a lower risk of hospital mortality [odds ratio (OR) 0.82, 95% confidence interval (CI) 0.67–0.99] compared to the reference stratum (110–140 mg/dL), while the other strata were still associated with higher risks of hospital mortality (OR >1) (Figure 4).

In the subgroup analyses stratified by diabetes, consistent results were found among patients without diabetes, but for patients with diabetes, an average blood glucose




Figure 3 Associations between maximum blood glucose levels within 24 hours after ICU admission and hospital mortality. Notes: Adjusted for age, sex, ethnicity, type of admission, SAPS II on admission, mechanical ventilation on first day, renal replacement therapy on first day, and Elixhauser Comorbidity Index (SID30).

ranged 140–180 mg/dL was associated with a lower risk of hospital mortality (OR 0.98, 95% CI 0.64–1.51) compared to the reference stratum (110–140 mg/dL). Detailed estimations for each stratum together with associations with ICU mortality and 28-day mortality are presented in Tables 4–6.

Discussion

The study investigated the associations of blood glucose levels within 24 hours after ICU admission with various clinical outcomes using data from a large critical care database, in which about 14,000 mixed ICU patients were included and several potential confounders were adjusted including a disease severity score and a comorbidity score. Results of the study mainly indicated that an average blood glucose ranged 110–140 mg/dL within 24 hours after ICU admission was associated with better prognosis when compared with other ranges, and the association was solid among patients without diabetes.

Although there were already several observational studies available which investigated a similar association, results of our study will be a fair supplement to the evidence




Figure 4 Associations between minimum blood glucose levels within 24 hours after ICU admission and hospital mortality. Notes: Adjusted for age, sex, ethnicity, type of admission, SAPS II on admission, mechanical ventilation on first day, renal replacement therapy on first day, and Elixhauser Comorbidity Index (SID30).

about the association between blood glucose levels and prognosis of ICU patients. Compared with other observational studies, our study had some different characteristics. Unlike some studies which only focused on patients with trauma or brain injury,^{8,10,11,13–15} the study investigated a mixed population of ICU patients and a model including a comorbidity score was employed to adjust for potential confounders. Therefore, results of the study may be seen as an average evaluation of the associations. When compared with observational studies that looked at general population of critically ill patients, the analysis methods and the results of our study were not exactly the same. Krinsley² retrospectively analyzed data of 1826 mixed ICU patients and compared the mean and maximum glucose between survivors and nonsurvivors, concluding that patients with a mean glucose ranged 80-99 mg/dL had the lowest hospital mortality; however, our study supported an average glucose ranged

110-140 mg/dL associated with better prognosis, but it should be aware that our study used a different analysis strategy. Instead of treating blood glucose as a continuous variable, in the study it was a priori categorized as <60, 60-80, 80-110, 110-140, 140-180, 180-200, and ≥200 mg/ dL; another difference was that only blood glucose records within 24 hours after ICU admission were taken into consideration. The reason why these strata were used was that most of these strata were investigated in various clinical trials.^{4,21} Lanspa et al¹² used a wider range (70–139 mg/ dL) as the target and found that the time in targeted blood glucose >80% was associated with reduced mortality especially in nondiabetic patients. To some extent, this conclusion was consistent with our study, since in our study the stratum ranged 110-140 mg/dL and 80-110 mg/dL had the first and second lowest OR for hospital mortality compared with other strata especially in patients without diabetes, but

Average Blood Glucose Levels	Crude		Adjusted*		Adjusted*			
(mg/dL)					Without Diabetes		Diabetes	
	OR/HR	95% CI	OR/HR	95% CI	OR/HR	95% CI	OR/HR	95% CI
Hospital mortality								
<60	1.09	0.15-8.17	0.70	0.09–5.48	1.35	0.16-11.72	-	-
60–80	2.14	1.40-3.26	1.28	0.81-2.03	1.34	0.78–2.30	1.07	0.44-2.63
80-110	1.15	0.94-1.41	1.11	0.90-1.38	1.11	0.87-1.40	1.11	0.65-1.89
110–140	1	Reference	1	Reference	1	Reference	1	Reference
140–180	1.33	1.10-1.61	1.15	0.94-1.41	1.27	1.01-1.59	0.98	0.64-1.51
180–200	1.71	1.27–2.28	1.46	1.07-1.98	1.66	1.11–2.48	1.38	0.82-2.32
≥200	1.59	1.25–2.02	1.23	0.96–1.58	1.77	1.25–2.52	1.09	0.71-1.68
ICU mortality								
<60	-	-	-	-	-	-	-	_
60–80	3.26	1.12–9.50	2.95	0.97–8.98	2.65	0.74–9.45	6.05	0.53-69.29
80-110	0.97	0.49–1.91	1.19	0.59–2.40	1.31	0.64–2.69	-	-
110–140	1	Reference	1	Reference	1	Reference	1	Reference
140–180	1.93	1.12–3.32	1.51	0.86–2.64	1.52	0.82-2.81	2.29	0.56–9.40
180–200	3.40	1.68–6.86	2.57	1.23-5.34	3.52	1.57–7.88	1.40	0.21-9.38
≥200	4.74	2.74-8.18	3.31	1.86–5.88	5.08	2.61–9.89	3.06	0.76-12.28
28-day mortality								
<60	-	_	-	-	-	_	-	-
60–80	1.99	1.40-2.82	1.23	0.87-1.75	1.18	0.77–1.80	1.34	0.70-2.55
80-110	1.14	0.96-1.35	1.11	0.93-1.31	1.09	0.90-1.31	1.15	0.76–1.7
110–140	1	Reference	1	Reference	1	Reference	1	Reference
140–180	1.21	1.04-1.42	1.08	0.92-1.27	1.14	0.95-1.38	1.00	0.71-1.39
180–200	1.51	1.18–1.93	1.36	1.06-1.74	1.47	1.06-2.03	1.38	0.91-2.08
≥200	1.37	1.12–1.68	1.15	0.94-1.41	1.66	1.25-2.20	1.01	0.72-1.44

Table 4 Associations Between Average Blood Glucose Levels Within 24 Hours After ICU Admission and Clinical Outcomes

Notes: *Adjusted for age, sex, ethnicity, type of admission, SAPS II on admission, mechanical ventilation on first day, renal replacement therapy on first day, and Elixhauser Comorbidity Index (SID30).

Abbreviations: ICU, intensive care unit; OR, odds ratio; HR, hazard ratio; CI, confidence interval.

interpreting results of our study should be cautious since only blood glucose within 24 hours after ICU admission was looked at, which might be more related to the illness itself, or put it in other words, might be merely a marker of illness severity. We also evaluated the associations of blood glucose with other clinical outcomes including ICU mortality and 28day mortality, and results were similar. Although there were also a few clinical trials which investigated the similar association,^{19–21} results of our study could not be directly compared to them, because the clinical trials were designed and conducted to determine the optimal target of glucose control, while the study aimed to evaluate the association between blood glucose within 24 hours after ICU admission and prognosis.

One more thing that needs to discuss is about the interpretation of the results. As presented in Tables 4–6, there were quite a lot of borderline confidence intervals of

the associations between blood glucose levels and clinical outcomes. Although from a statistical point of view the confidence interval of a significant association should not include 1, most of these borderline results suggested a poorer prognosis compared with the reference stratum since they were toward an odds ratio or hazard ratio greater than $1.^{29}$

There are some potential limitations of the study. As a retrospective design, variables such as blood glucose levels before hospital admission were unavailable. The average of blood glucose might be affected by the number of blood glucose measurements, which was not taken into consideration in the study. Therapy for controlling blood glucose was also not considered, but since only blood glucose in the first 24 hours after ICU admission was studied, it may be not that important. However, based on the design of the study, it should be award that results of the study should not be seen

Minimum Blood Glucose Levels	Crude		Adjusted*		Adjusted*			
(mg/dL)					Without Diabetes		Diabetes	
	OR/HR	95% CI	OR/HR	95% CI	OR/HR	95% CI	OR/HR	95% CI
Hospital mortality								
<60	1.81	1.18–2.79	1.01	0.63-1.61	1.45	0.80–2.62	0.61	0.27-1.36
60–80	1.61	1.24-2.10	1.14	0.87-1.51	1.12	0.80-1.56	1.15	0.69–1.91
80-110	0.87	0.72-1.04	0.82	0.67–0.99	0.84	0.68–1.04	0.68	0.45-1.04
110—140	1	Reference	1	Reference	1	Reference	1	Reference
140–180	1.51	1.22-1.86	1.37	1.10-1.71	1.63	1.25-2.12	1.04	0.69–1.57
180–200	1.37	0.88-2.13	1.21	0.76–1.93	2.21	1.23-3.98	0.63	0.28-1.42
≥200	1.47	1.02-2.14	1.12	0.75-1.66	1.83	0.99–3.39	0.91	0.52-1.58
ICU mortality								
<60	2.54	0.88–7.31	1.69	0.55–5.20	1.64	0.43-6.18	1.91	0.20-17.97
60–80	1.40	0.63–3.09	1.33	0.59–3.01	1.28	0.50–3.27	1.49	0.27-8.21
80-110	0.75	0.43-1.32	0.83	0.47–1.46	0.85	0.46-1.58	0.62	0.14-2.78
110–140	1	Reference	1	Reference	1	Reference	1	Reference
140–180	2.89	1.73-4.82	2.70	1.59-4.59	3.17	1.75–5.75	1.99	0.59–6.65
180–200	2.66	1.02-6.96	2.40	0.88–6.57	3.51	1.10-11.20	1.47	0.16-13.28
≥200	4.68	2.36–9.31	3.24	1.53–6.85	6.96	2.82-17.23	1.41	0.30–6.63
28-day mortality								
<60	1.628	1.127–2.352	0.959	0.66–1.392	1.1	0.674–1.795	0.82	0.46-1.48
60–80	1.497	1.2-1.868	1.102	0.881–1.378	1.02	0.774–1.345	1.23	0.83-1.82
80–110	0.924	0.795-1.074	0.874	0.752-1.017	0.907	0.764–1.075	0.72	0.52-1.01
110–140	1	Reference	1	Reference	1	Reference	1	Reference
140–180	1.386	1.16-1.655	1.285	1.075–1.535	1.516	1.225–1.877	1.01	0.73-1.40
180–200	1.177	0.795–1.742	1.09	0.736-1.614	1.728	1.056–2.829	0.71	0.37–1.37
≥200	1.396	1.019-1.912	1.149	0.838-1.574	1.808	1.119–2.923	0.96	0.62-1.49

Table 5 Associations Between Minimum Blood Glucose Levels Within 24 Hours After ICU Admission and Clinical Outcomes

Notes: *Adjusted for age, sex, ethnicity, type of admission, SAPS II on admission, Mechanical ventilation on first day, Renal replacement therapy on first day, and Elixhauser Comorbidity Index (SID30).

Abbreviations: ICU, intensive care unit; OR, odds ratio; HR, hazard ratio; CI, confidence interval.

Maximum Blood Glucose Levels	Crude		Adjusted*		Adjusted*			
(mg/dL)					Without Diabetes		Diabetes	
	OR/HR	95% CI	OR/HR	95% CI	OR/HR	95% CI	OR/HR	95% CI
Hospital mortality								
<60	3.12	0.38–25.52	2.29	0.26-20.53	6.22	0.54–72.28	-	-
60–80	3.09	1.73–5.52	1.86	0.98–3.52	2.58	1.26-5.29	0.68	0.14-3.30
80–110	1.17	0.91-1.51	1.09	0.83-1.42	1.05	0.79–1.41	1.24	0.63–2.43
110–140	1	Reference	1	Reference	1	Reference	1	Reference
140–180	1.36	1.11–1.66	1.26	1.02-1.55	1.32	1.05-1.66	1.13	0.68–1.87
180–200	1.37	1.02-1.84	1.08	0.80-1.47	1.12	0.78–1.60	1.10	0.59–2.05
≥200	1.63	1.32–2.00	1.18	0.95–1.46	1.40	1.07–1.84	1.14	0.72–1.79
ICU mortality								
<60	-	-	-	-	-	-	-	-
60–80	3.63	0.84–15.71	2.81	0.61-12.90	3.46	0.73–16.38	-	-
80-110	0.64	0.26-1.60	0.69	0.27-1.75	0.59	0.22-1.61	2.85	0.16-50.54
110–140	1	Reference	1	Reference	1	Reference	1	Reference
140–180	1.31	0.73–2.35	1.00	0.55-1.83	0.98	0.53–1.84	2.23	0.22-22.38
180–200	1.29	0.54–3.05	0.82	0.34-1.99	1.09	0.45–2.68	_	-
≥200	3.41	2.03–5.73	1.99	1.16–3.42	2.14	1.17–3.91	5.87	0.74–46.39
28-day mortality								
<60	-	_	_	_	-	-	-	-
60–80	2.14	1.27-3.60	1.20	0.71-2.03	1.31	0.71-2.41	1.02	0.36–2.86
80–110	1.18	0.96-1.44	1.10	0.90-1.35	1.08	0.86-1.35	1.20	0.72–2.02
110–140	1	Reference	1	Reference	1	Reference	1	Reference
140–180	1.18	1.00-1.39	1.10	0.93-1.30	1.15	0.96-1.38	1.01	0.68–1.50
180–200	1.18	0.92-1.51	0.97	0.76-1.24	0.91	0.67–1.23	1.17	0.73–1.88
≥200	1.40	1.18–1.66	1.09	0.92-1.29	1.28	1.03-1.59	1.05	0.73-1.49

Notes: *Adjusted for age, sex, ethnicity, type of admission, SAPS II on admission, mechanical ventilation on first day, renal replacement therapy on first day, and Elixhauser Comorbidity Index (SID30).

Abbreviations: ICU, intensive care unit; OR, odds ratio; HR, hazard ratio; CI, confidence interval.

as an evidence that support a blood glucose ranged 110–140 mg/dL (or 80–140 mg/dL) as the optimal target of glucose control for ICU patients. Due to the concern about limited sample sizes in some blood glucose strata, reasons for ICU admission were also not taken into consideration. In addition, the study did not research other clinical outcomes such as hypoglycemia or nosocomial infection which might be important in clinical practice. The potential association between variability of blood glucose and prognosis might be also an interesting point to explore in further studies.

Conclusion

A range of 110–140 mg/dL for average and maximum blood glucose and a range of 80–110 mg/dL for minimum blood glucose within 24 hours after ICU admission predicted better prognosis especially among patients without diabetes. Further studies especially randomized controlled trials are needed to explore whether this range could be an optimal target for blood glucose control in the early stage after ICU admission.

Abbreviations

ICU, intensive care unit; MIMIC-III, Medical Information Mart for Intensive Care III; SAPS II, Simplified Acute Physiology Score II; LOINC, Logical Observation Identifiers Names and Codes; OR, odds ratio; CI, confidence interval; AIDS, acquired immune deficiency syndrome; SD, standard deviation; HR, hazard ratio.

Funding

This work was supported by the National Natural Science Funds for Young Scholars of China (81800416) and Guangzhou Major Program of the Industry-University-Research Collaborative Innovation (201508020116).

Disclosure

The authors report no conflicts of interest in this work.

References

- Kosiborod M, Inzucchi SE, Spertus JA, et al. Elevated admission glucose and mortality in elderly patients hospitalized with heart failure. *Circulation*. 2009;119:1899–1907. doi:10.1161/ CIRCULATIONAHA.108.821843
- Krinsley JS. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. *Mayo Clin Proc.* 2003;78:1471–1478. doi:10.4065/78.12.1471
- Schmeltz LR, DeSantis AJ, Thiyagarajan V, et al. Reduction of surgical mortality and morbidity in diabetic patients undergoing cardiac surgery with a combined intravenous and subcutaneous insulin glucose management strategy. *Diabetes Care*. 2007;30:823–828. doi:10.2337/dc06-2184
- van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. *N Engl J Med.* 2001;345:1359–1367. doi:10.1056/NEJMoa011300
- Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycaemia. Lancet (London, England). 2009;373:1798–1807. doi:10.1016/ S0140-6736(09)60553-5
- Farrokhi F, Smiley D, Umpierrez GE. Glycemic control in non-diabetic critically ill patients. *Best Pract Res Clin Endocrinol Metab.* 2011;25:813–824. doi:10.1016/j.beem.2011.05.004
- 7. Chinsky K. The evolving paradigm of hyperglycemia and critical illness. *Chest.* 2004;126:674–676. doi:10.1378/chest.126.3.674
- Bochicchio GV, Sung J, Joshi M, et al. Persistent hyperglycemia is predictive of outcome in critically ill trauma patients. *J Trauma*. 2005;58:921–924. doi:10.1097/01.ta.0000162141.26392.07
- Falciglia M, Freyberg RW, Almenoff PL, D'Alessio DA, Render ML. Hyperglycemia-related mortality in critically ill patients varies with admission diagnosis. *Crit Care Med*.2009;37:3001–3009. doi:10.1097/CCM.0b013e3181b083f7
- Jeremitsky E, Omert LA, Dunham CM, Wilberger J, Rodriguez A. The impact of hyperglycemia on patients with severe brain injury. *J Trauma*. 2005;58:47–50. doi:10.1097/01.ta.0000135158.42242.b1
- Laird AM, Miller PR, Kilgo PD, Meredith JW, Chang MC. Relationship of early hyperglycemia to mortality in trauma patients. *J Trauma*. 2004;56:1058–1062. doi:10.1097/01.ta.0000123267.39011.9f
- Lanspa MJ, Krinsley JS, Hersh AM, et al. Percentage of time in range 70 to 139 mg/dl is associated with reduced mortality among critically ill patients receiving IV Insulin infusion. *Chest.* 2019;156:878–886. doi:10.1016/j.chest.2019.05.016
- Rovlias A, Kotsou S. The influence of hyperglycemia on neurological outcome in patients with severe head injury. *Neurosurgery*. 2000;46:335– 342; discussion 342–333. doi:10.1097/00006123-200002000-00015
- Sung J, Bochicchio GV, Joshi M, Bochicchio K, Tracy K, Scalea TM. Admission hyperglycemia is predictive of outcome in critically ill trauma patients. *J Trauma*.2005;59:80–83. doi:10.1097/01.TA.00001 71452.96585.84

- Yendamuri S, Fulda GJ, Tinkoff GH.Admission hyperglycemia as a prognostic indicator in trauma. J Trauma.2003;55:33–38. doi:10.1097/01.TA.0000074434.39928.72
- Fahy BG, Sheehy AM, Coursin DB. Glucose control in the intensive care unit. *Crit Care Med.* 2009;37:1769–1776. doi:10.1097/ CCM.0b013e3181a19ceb
- 17. Qaseem A, Humphrey LL, Chou R, Snow V, Shekelle P, Clinical Guidelines Committee of the American College of P. Use of intensive insulin therapy for the management of glycemic control in hospitalized patients: a clinical practice guideline from the American College of Physicians. *Ann Intern Med.* 2011;154:260–267. doi:10.7326/0003-4819-154-4-201102150-00007.
- Chase JG, Desaive T, Bohe J, et al. Improving glycemic control in critically ill patients: personalized care to mimic the endocrine pancreas. *Crit Care*. 2018;22:182. doi:10.1186/s13054-018-2110-1
- Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008;358:125–139. doi:10.1056/NEJMoa070716
- 20. Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360:1283–1297. doi:10.1056/NEJMoa0810625
- Preiser JC, Devos P, Ruiz-Santana S, et al. A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. *Intensive Care Med.* 2009;35:1738–1748. doi:10.1007/s00134-009-1585-2
- Cohen AT, Goto S, Schreiber K, Torp-Pedersen C. Why do we need observational studies of everyday patients in the real-life setting? *Eur Heart Jl Suppl.* 2015;17:D2–D8. doi:10.1093/eurheartj/suv035
- 23. Celi LA, Mark RG, Stone DJ, Montgomery RA. Big data" in the intensive care unit. Closing the data loop. Am J Respir Crit Care Med. 2013;187:1157–1160. doi:10.1164/rccm.201212-2311ED
- Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. *Adv Ther.* 2018;35:1763–1774. doi:10.1007/s12325-018-0805-y
- Johnson AE, Pollard TJ, Shen L, et al. MIMIC-III, a freely accessible critical care database. *Sci Data*. 2016;3:160035. doi:10.1038/ sdata.2016.35
- 26. Johnson AE, Stone DJ, Celi LA, Pollard TJ. The MIMIC code repository: enabling reproducibility in critical care research. J Am Med Inform Assoc. 2018;25:32–39. doi:10.1093/jamia/ocx084
- 27. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. *JAMA*. 1993;270:2957–2963. doi:10.1001/ jama.270.24.2957
- Thompson NR, Fan Y, Dalton JE, et al. A new elixhauser-based comorbidity summary measure to predict in-hospital mortality. *Med Care*, 2015;53:374–379. doi:10.1097/MLR.00000000000326
- Hackshaw A, Kirkwood A. Interpreting and reporting clinical trials with results of borderline significance. *BMJ*. 2011;343:d3340. doi:10.1136/bmj.d3340

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

Dovepress

Publish your work in this journal

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy is an international, peer-reviewed open-access journal committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion and commentaries are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-targets-and-therapy-journal